Healthcare, Pharma & Life Sciences

Wooster, Ohio – November 06, 2026 -- PRC-Saltillo, an augmentative and alternative communication (AAC) technology maker founded in 1966, has partnered with the Team Gleason Foundation to expand awareness, education and access to assistive communication technology for people with ALS and their families.

Partnership targets shifting communication needs across the ALS journey

The companies say communication needs change as ALS progresses. Navigating technologies, resources and support can overwhelm patients, care partners and clinicians alike. The partnership will deliver educational opportunities, share expertise and raise awareness of available communication solutions.

Ipswich – November 06, 2026 -- New England Biolabs (NEB) will present an integrated cfDNA and cfRNA workflow, an enzymatic DNA methylation method and a new high-fidelity PCR master mix at the Association for Molecular Pathology (AMP) Annual Meeting & Expo, held November 10-15, 2026, at the Seattle Convention Center.

NEB workshop combines Monarch purification with NEBNext library prep for multiomic profiling

The corporate workshop, "One Sample, Many Insights: Multiomic Profiling in cfDNA and cfRNA Samples," runs Wednesday, November 11, at 10:00 AM in Tahoma 3, Level 3. It pairs Monarch Nucleic Acid Purification with NEBNext NGS Library Preparation. The workflow covers extraction through sequencing, and NEB says it is designed to recover mutation, methylation and gene-expression signals from limited samples.

Berlin – November 06, 2026 -- Participants at the 34th Plattform Gesundheit of IKK e.V. agreed that Germany's primary care reform must proceed step by step and without disruptive breaks, with quality taking priority over speed. Representatives from health policy, the medical profession and self-governance, plus about 100 guests attending on site and online, debated how a primary care system can steer patients to the right level of care without becoming an additional access barrier.

SAN FRANCISCO – November 06, 2026 -- AusperBio's investigational antisense oligonucleotide AHB-137 maintained functional cure in 16 of 17 evaluable nucleos(t)ide analogue (NA)-treated chronic hepatitis B participants 12 months after they stopped all HBV treatment, according to long-term follow-up data from Study AB-10-8004. No participant required NA re-initiation during follow-up.

Nine of nine evaluable NA-treated participants stay cured at 15 months

In the NA-treated cohort, functional cure held in 9 of 9 evaluable participants at 15 months after NA discontinuation. The cohort enrolled 34 participants (21 complete responders, 13 partial responders) from the Phase 2 studies AB-10-8002 and AB-10-8003.

Durham – November 06, 2026 -- Brii Biosciences (2137.HK) reported that 41.9% of participants (62/148) in its Phase 2b ENRICH study achieved hepatitis B surface antigen (HBsAg) loss at end of treatment (EOT), with 32.4% (48/148) sustaining it 24 weeks later. The data were presented in three late-breaking sessions at the AASLD Liver Meeting in Denver, running November 5 to 9, 2026.

ENRICH reproduces the BRII-179 priming effect seen in ENSURE Cohort 4

ENRICH prospectively tested a strategy first identified in Cohort 4 of the ENSURE study, where BRII-179-experienced participants, particularly those developing anti-HBs responses, showed higher functional cure rates. Participants received BRII-179 every 3 or 2 weeks for 12 weeks before elebsiran and pegylated interferon alpha (PEG-IFNα). Results across both dose regimens matched the ENSURE observations.

BELLEVUE – November 06, 2026 -- Harrison Street Asset Management, a firm with more than $110 billion in assets under management, has formed a joint venture with Aegis Living to invest in and develop assisted living and memory care communities, starting with a three-property portfolio.

Initial portfolio covers three Aegis communities in Washington and California

The first investment spans Aegis Gardens in Newcastle, WA; Aegis Living Moraga in Moraga, CA; and Aegis Living Madison in Seattle. The partners plan to add acquisitions and development projects. Financial terms were not included in the announcement.

Aegis Living will continue to manage all three communities. Care teams, community leaders and care plans stay in place. Aegis, founded in 1997 and based in Bellevue, operates 37 communities across Washington, California and Nevada.

Addison, Texas – November 06, 2026 -- FX Shoulder Solutions has received FDA 510(k) clearance for Easytech Reversed, which the company describes as the first and only stemless reverse shoulder arthroplasty system cleared in the United States. The clearance follows nearly eight years of US clinical investigation.

Seven-site IDE study enrolled 90 patients

FX started the US Investigational Device Exemption (IDE) study in 2018. The multicenter investigation ran across seven sites and covered 90 patients. Follow-up was completed in 2023 and supports the regulatory submission, according to the company. FX also cites more than a decade of international clinical experience with its Easytech technology.

Shanghai – November 06, 2026 -- Antengene Corporation Limited (SEHK: 6996.HK) has dosed the first patient in China in the Phase I ATTRACT study of ATG-201, its CD19 x CD3 bispecific T-cell engager (TCE) for adult patients with B cell-mediated autoimmune diseases. UCB holds worldwide exclusive rights to develop, manufacture and commercialize the asset.

UCB holds global rights while Antengene runs Phase I in China and Australia

Under the agreement, UCB also gains access to the manufacturing technology associated with ATG-201. Antengene remains responsible for conducting the Phase I trials in China and Australia.

The Australian arm has cleared its regulatory steps. ATG-201 has obtained approval from the Human Research Ethics Committee (HREC) and completed the Clinical Trial Notification (CTN) process with the Therapeutic Goods Administration (TGA).

Tampa – November 06, 2026 -- Medicare will pay a national non-facility (office) rate of approximately $19,441 for CPT code 27279 starting January 1, 2027, according to PainTEQ's reading of the CMS Calendar Year 2027 Physician Fee Schedule Final Rule (CMS-1848-F). The code covers percutaneous or minimally invasive sacroiliac (SI) joint arthrodesis using devices with intrinsic fixation that pierce the cortices. It had no office rate before that date.

CMS finalizes practice expense inputs that create the first office rate for 27279

Under the 2026 Physician Fee Schedule, code 27279 carried a facility payment rate only. For 2027, CMS finalized the RUC-recommended practice expense inputs, which produce the new office rate. The $19,441 figure is before geographic adjustment, sequestration and patient cost sharing, and actual payment varies by locality.

Boulder – November 06, 2026 -- An estimated 3.29 to 3.98 million U.S. adults have severe hypertriglyceridemia, but only 2.43 to 2.88 million have been diagnosed, according to a white paper released by the National Triglyceride Alliance. The gap implies roughly 0.86 to 1.10 million adults who are undiagnosed.

The paper, titled "Hidden in Plain Sight: The Unseen Burden of Very High Triglycerides," was supported by Ionis Pharmaceuticals. Patient, care partner, clinical and advocacy contributors helped develop it. It defines the condition as triglycerides of 500 mg/dL or higher.